诺迪康品牌怎么样 申请店铺

我要投票 诺迪康在中草药行业中的票数:1084 更新时间:2025-12-14
诺迪康是哪个国家的品牌?「诺迪康」是 西藏诺迪康药业股份有限公司 旗下著名品牌。该品牌发源于西藏,由创始人陈达彬在1999-07-14期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。

外推网助力诺迪康品牌出海!将品牌入驻外推网,定制诺迪康品牌推广信息,可以显著提高诺迪康产品曝光,简直是跨境电商爆单神器!目前仅需1000元/年哦~

诺迪康怎么样

西藏诺迪康药业股份有限公司是西藏雪域高原上诞生的第一家高新技术制药上市企业,于1999年7月14日创立,1999年7月21日在上海证券交易所上网交易,股票名称:西藏药业,股票代码:600211。

在各级领导的关心和支持下,公司已经发展成为一家拥有员工4000余人,总资产8.2亿元的现代化制药企业。公司累计上缴税金2亿余元,发放员工工资、福利2.2亿余元;公司主要产品诺迪康胶囊年销售额逾亿元,公司生物一类新药重组人脑利钠肽也已经上市销售。

公司拥有西藏诺迪康医药有限公司、成都诺迪康生物制药有限公司、四川诺迪康威光制药有限公司、西藏康达药业有限公司、西藏诺迪康藏药材开发有限公司、四川本草堂药业有限公司等下属子公司。

公司秉承“科学成就健康,健康成就未来”的理念,以科技兴业。在为藏药现代化不遗余力的同时,公司注巨资于生物制品和传统药品的研发,并构建了林芝种植基地和四个生产基地及覆盖全国的营销网络。产品涵盖生物制品、藏药和中药、化学药的产品系列,奠定了西藏药业持续发展的基础,其中具有自主知识产权的生物制品一类新药新活素,代表着目前国际急性心衰急救治疗药物的最高水平,填补了该领域的国内空白。

公司上市以来连续被西藏自治区认定为高新技术企业、西藏自治区农牧业龙头企业,2001年被国家科学技术部认定为国家火炬计划重点高新技术企业。2008年公司被科技部认定为创新型试点企业。公司图形商标(祥云图)经国家工商总局认定为中国驰名商标,公司产品诺迪康胶囊和十味蒂达胶囊被评为国家中药保护品种,同时,还被国家保密局、科学技术部评为秘密级国家秘密技术。

经过多年来的不懈努力,公司已成为拥有一个国家级企业技术中心、四个符合GMP规范的药品生产基地、一个符合GAP藏药材种植基地及覆盖全国的营销网络,集藏药产品、植物药产品、化学药产品、生物制品研发、生产和销售一体的现代化企业。

Tibet nordikang Pharmaceutical Co., Ltd. is the first high-tech pharmaceutical listed enterprise born on the snow capped plateau of Tibet. It was founded on July 14, 1999 and traded on the Internet at Shanghai Stock Exchange on July 21, 1999. Its stock name is Tibet pharmaceutical, and its stock code is 600211. With the concern and support of leaders at all levels, the company has developed into a modern pharmaceutical enterprise with more than 4000 employees and total assets of 820 million yuan. The company has paid taxes of more than 200 million yuan and paid employees salaries and welfare of more than 220 million yuan; the annual sales volume of the company's main product, nordicon capsule, is more than 100 million yuan, and the company's new biological class I recombinant human brain natriuretic peptide has also been listed for sale. The company has subsidiaries including Tibet nordikang Pharmaceutical Co., Ltd., Chengdu nordikang biopharmaceutical Co., Ltd., Sichuan nordikang Weiguang Pharmaceutical Co., Ltd., Tibet Kangda Pharmaceutical Co., Ltd., Tibet nordikang Tibetan Medicine Development Co., Ltd., Sichuan bencaotang Pharmaceutical Co., Ltd. The company adheres to the concept of "science makes health, health makes future", and prospers with science and technology. While sparing no effort for the modernization of Tibetan medicine, the company has invested heavily in the research and development of biological products and traditional drugs, and has built the Linzhi planting base, four production bases and a nationwide marketing network. The products range from biological products, Tibetan medicine, traditional Chinese medicine and chemical medicine, laying the foundation for the sustainable development of Tibetan pharmaceutical industry, among which the biological products with independent intellectual property rights represent the highest level of international emergency treatment drugs for acute heart failure, and fill the domestic gap in this field. Since its listing, the company has been successively recognized as a high-tech enterprise in Tibet Autonomous Region, a leading enterprise in agriculture and animal husbandry in Tibet Autonomous Region, and a key high-tech enterprise in the national torch plan by the Ministry of science and technology of the people's Republic of China in 2001. In 2008, the company was recognized as an innovative pilot enterprise by the Ministry of science and technology. The company's graphic trademark (xiangyuntu) has been recognized as a well-known trademark in China by the State Administration of industry and commerce. The company's products, nordikang capsule and Shiweidida capsule, have been rated as the national traditional Chinese medicine protected varieties. Meanwhile, they have also been rated as the secret level national secret technology by the State Security Bureau and the Ministry of science and technology. After years of unremitting efforts, the company has become a modern enterprise with a national enterprise technology center, four GMP compliant pharmaceutical production bases, a gap compliant Tibetan medicine planting base and a nationwide marketing network, which integrates the research and development, production and sales of Tibetan medicine products, botanical medicine products, chemical medicine products and biological products.

本文链接: https://brand.waitui.com/0b45a7af1.html 联系电话:请联系客服添加 联系邮箱:请联系客服添加

外推网广告位招租,每天只要9块9

7×24h 快讯

2025年人工智能核心产业规模有望破万亿元

12月14日,从中国信息通信研究院了解到,今年以来,我国人工智能产业呈加速发展态势,2025年人工智能核心产业规模有望突破万亿元。数据显示,今年以来,生产制造环节的大模型应用增长显著,应用案例占比由去年的19.9%增长至25.9%,带动人工智能产业规模快速增长。(央视新闻)

43分钟前

近一周逾260家公司获机构调研 中科曙光和海光信息获调研数最多

近一周获得机构调研的个股有260多只,中科曙光和海光信息调研机构数最多。中科曙光和海光信息近一周有341家机构调研。中科曙光方面表示,尽管重组终止,但海光与曙光仍将在保持上市公司独立性基础上深化协同。安克创新、伟创电气等个股也均获得逾百家机构调研。从市场表现来看,近一周机构调研股月内平均上涨近1%。超捷股份、霍莱沃、斯瑞新材、博盈特焊、华菱线缆等个股均涨逾20%。(人民财讯)

43分钟前

调查:美联储明年1月降息25个基点的概率为24.4%

12月14日,据CME“美联储观察”:美联储2026年1月降息25个基点的概率为24.4%,维持利率不变的概率为75.69%。美联储到明年3月累计降息25个基点的概率为41.4%,维持利率不变的概率为50.5%,累计降息50个基点的概率为8.1%。(界面新闻)

44分钟前

万科三个展期议案均未获通过 仍有5个工作日宽限期

12月13日公告显示,万科“22万科MTN004”持有人会议三项展期议案均未获有效通过,核心展期规则均为展期一年且期间不付本息,差异在增信安排。议案一未设增信,无人同意;议案二增信加调整本息兑付,获83.40%同意;议案三仅一票同意。万科还有5个工作日宽限期谈判。(新浪财经)

44分钟前

2030年我国天然气产量将达3000亿立方米

《中国油气行业“十四五”发展成就报告》显示,中国正加速迈向现代油气产业发展新阶段,能源结构日趋多元均衡,2030年我国天然气产量将达到3000亿立方米。报告显示,“十四五”期间我国累计新增探明地质储量石油70亿吨、天然气7万亿立方米,分别较“十三五”增长约43%、40%,油气产量创历史新高。(央视新闻)

44分钟前

本页详细列出关于诺迪康的品牌信息,含品牌所属公司介绍,诺迪康所处行业的品牌地位及优势。
咨询